Olaparib
- Generic Name
- Olaparib
- Brand Names
- Lynparza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23FN4O3
- CAS Number
- 763113-22-0
- Unique Ingredient Identifier
- WOH1JD9AR8
- Background
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...
- Indication
Ovarian cancer
Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
- Associated Therapies
- Maintenance therapy
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
- Conditions
- Interventions
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 384
- Registration Number
- NCT02484404
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Platine, Avastin and OLAparib in 1st Line
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Arcagy Research
- Target Recruit Count
- 806
- Registration Number
- NCT02477644
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Krankenhaus Hietzing, Vienna, Austria
🇧🇪CHU Dinant Godinne, Yvoir, Belgium
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 181
- Registration Number
- NCT02476968
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Endometrioid TumorOvarian Seromucinous CarcinomaOvarian Serous TumorOvarian Transitional Cell CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma
- Interventions
- Drug: CarboplatinProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: Cediranib MaleateProcedure: EchocardiographyDrug: GemcitabineDrug: Gemcitabine HydrochlorideOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: OlaparibProcedure: Multigated Acquisition ScanOther: Pharmacological StudyOther: Quality-of-Life AssessmentDrug: PaclitaxelDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 579
- Registration Number
- NCT02446600
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Atrium Health Navicent, Macon, Georgia, United States
🇺🇸Legacy Mount Hood Medical Center, Gresham, Oregon, United States
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Zofia Piotrowska
- Target Recruit Count
- 66
- Registration Number
- NCT02446704
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02430311
- Locations
- 🇨🇳
Research Site, Hangzhou, China
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 50
- Registration Number
- NCT02398058
- Locations
- 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
🇮🇹Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy
🇮🇹Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, Italy
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02392676
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
- Conditions
- Ovarian CarcinomaPrimary Peritoneal CarcinomaPrimary Peritoneal Serous AdenocarcinomaFallopian Tube CarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaOvarian High Grade Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPrimary Peritoneal Endometrioid Adenocarcinoma
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT02345265
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.